News for Healthier Living

Survival Disparities Increase for Patients Without Health Insurance Following FDA Approval of Immune Checkpoint Inhibitors for Advanced Cancers, New ACS Study Shows

In a new study led by the American Cancer Society, researchers found that the introduction of immune checkpoint inhibitors (ICIs) following FDA approval was associated with a widening survival disparity between people without health insurance and those with private insurance, newly diagnosed with advanced stage melanoma, non-small cell lung cancer, or renal cell carcinoma (kidney cancer). ICIs are a type of advanced immunotherapy and work by helping the immune system better find and attack cancer cells in the body. While offering promising outcomes for many patients, ICIs are also among the highest-cost cancer drugs.

July 7, 2025


July 7 2025

July 6 2025

July 5 2025

July 4 2025

July 3 2025

July 2 2025

July 1 2025

June 30 2025

June 29 2025

June 28 2025

June 27 2025

June 26 2025

June 25 2025

June 24 2025

June 23 2025